Rekombinanter ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper

Produktnummer ABIN7200659

Dieser Humanized Monoklonal Antikörper detektiert spezifisch ErbB2/Her2 (Trastuzumab Biosimilar) in FACS und in vivo. Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für Rekombinanter ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper (ABIN7200659)

Target: ErbB2/Her2 (Trastuzumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Humanized

Klonalität: Monoklonal

Konjugat: Dieser ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Klon: 4D5-8

Produktdetails anti-ErbB2/Her2 (Trastuzumab Biosimilar) Antikörper

Verwendungszweck: Trastuzumab Biosimilar, HER2 Monoclonal Antibody

Spezifität: The monoclonal antibody trastuzumab biosimilar specifically binds to the human HER2 / ErbB-2 / c-neu.

Produktmerkmale: Trastuzumab, a humanized monoclonal antibody, interferes with the HER2/neu receptor and is mainly used to treat certain breast cancers, especially HER2-positive metastatic breast cancer. Combined with chemotherapy, trastuzumab increases both survival and response rate. There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1, HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, the HER receptors embedded in the cell membrane promote cell growth and division by turning genes on and off. The HER2 pathway stimulates cell proliferation if it normally functions, when HER2 is overexpressed, cell growth accelerates beyond its normal limits, which happens in some cancers, notably certain types of breast cancer.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: The monoclonal antibody trastuzumab biosimilar was produced in the trastuzumab biosimilar CHO stable cell line.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by trastuzumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Lagerung: 4°C,-20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu ErbB2/Her2 (Trastuzumab Biosimilar)

Target: ErbB2/Her2 (Trastuzumab Biosimilar)

Andere Bezeichnung: Trastuzumab Biosimilar

Substanzklasse: Biosimilar